SCHEMBL1098490

SCHEMBL1098490

CC(=O)c1c(N(CCCCC(F)(F)F)S(=O)(=O)c2ccc(C#N)cc2)sc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.42
NFE2L2 Q16236 2/20 0.42
PSEN1 P49768 6/20 0.40
PSEN2 P49810 6/20 0.40
APH1B Q8WW43 6/20 0.40
NCSTN Q92542 6/20 0.40
APH1A Q96BI3 6/20 0.40
PSENEN Q9NZ42 6/20 0.40
TRPM8 Q7Z2W7 3/20 0.38
RORC P51449 3/20 0.38
NR1H2 P55055 2/20 0.38
NR1I2 O75469 2/20 0.38
RORA P35398 1/20 0.38
RORB Q92753 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
TAS2R14 Q9NYV8 1/20 0.36
HCRTR2 O43614 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12000788 0.88 TRPM8 (0.40) KEAP1NFE2L2PSEN1PSEN2APH1B
SCHEMBL1099819 0.88 TRPM8 (0.40) KEAP1NFE2L2PSEN1PSEN2APH1B
SCHEMBL1107227 0.87 TRPM8 (0.46) KEAP1NFE2L2PSEN1PSEN2APH1B
SCHEMBL1107234 0.82 TRPM8 (0.48) KEAP1NFE2L2PSEN1PSEN2APH1B
SCHEMBL1099071 0.81 TRPM8 (0.54) TRPM8RORCNR1I2ESR1ESR2
SCHEMBL1099106 0.79 TRPM8 (0.63) TRPM8
SCHEMBL1098266 0.79 TRPM8 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1097613 0.78 TRPM8 (0.64) KEAP1NFE2L2PSEN1PSEN2APH1B
SCHEMBL1099940 0.78 TRPM8 (0.40) KEAP1NFE2L2TRPM8NR1I2ESR1
SCHEMBL1099432 0.78 RORC (0.42) TRPM8RORCNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 EP disclosed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885PSEN1 1735/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885PSEN1 1735/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 KEAP1 2521/4885NFE2L2 2965/4885PSEN1 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.